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IFN-g will induce upregulation of MHC-I, 
MHC-II, and PD-L1 in a time-dependent 
manner in the Yumm1.7-3.D8.B7 mouse 
melanoma model.
Figure 2. Experimental layout
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Background
• T cell recognition of tumor-derived antigens 
presented on major histocompatibility 
complex (MHC) is critical for effective anti-
tumor immune responses
• MHC class I (MHC-I) presents antigens to 
CD8+ T cells, whereas MHC-II presents 
antigens to CD4+ T cells 
• T cells become activated upon recognition 
of peptide-MHC along with co-stimulation
• Activation and T cell stimulation can also 
upregulate the immune checkpoints CTLA-
4 and PD-1 and inhibit T cells
• Interferon-gamma (IFN-g) can induce 
upregulation of MHC-I and PD-L1 (a ligand 
for PD-1) on most tumors and MHC-II on a 
minority of tumors including some 
melanomas (1-3)
• MHC-II is usually expressed on antigen 
presenting cells (APCs) like macrophages 
and dendritic cells
• The role of MHC-II expression in melanoma 
and how this affects that anti-tumor immune 
responses is unclear 
• We evaluated expression of MHC-I, MHC-
II, PD-L1, and the co-stimulatory molecule 
CD80 on the Yumm1.7-3.D8.B7 melanoma 
cell line engineered to express model tumor 
antigens in the presence of absence of IFN-
g stimulatory conditions
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Results
• Yumm1.7-3.D8.B7 cells without IFN-g
stimulation expressed little to no MHC-I, 
MHC-II, and PD-L1. (Figure 4 and 5)
• IFN-g induced upregulation of MHC-I and 
PD-L1. (Figure 3, 4 and 5)
• MHC-I and PD-L1 expression dropped for 
cells stimulated with 300 u/mL IFN-g for 
72 hours compared to 100 u/mL treatment 
group. (Figure 3)
• MHC-I expression was identified on more 
than 90% of cells treated with IFN-g, 
peaking near 99% at 300 u/mL of IFN-g. 
(Figure 5)
• IFN-g induced upregulation of MHC-II, but 
only on a subset of melanoma cells.
• The percent of MHC-II expressing tumor 
cells increased from about 12.7% to 
18.2% when increasing dosage of IFN-g
from 100 u/mL to 300 u/mL. (Figure 4) 
• CD80 was constitutively expressed on 
Yumm1.7-3.D8.B7. (Figure 6)
Figure 6. CD80 expression histograms between 
24 and 72 hour incubation group
Red = 0 u/mL IFN-g
Blue = 100 u/mL IFN-g
















Figure 4. MHC-II (vertical) and PD-L1 (horizontal) expression 
dot chart. 
Figure 1. List of fluorescently conjugated antibodies 
used for the experiment. Isotype-matched control 
conjugated antibodies were added in separate 















Figure 5. MHC-I expression dot chart. Double 
positive would imply MHC-I expression
• The cells were stained in dark at 4℃ for 
30 minutes. Afterwards, they were 
washed with 200 ul of FACS buffer
• Cells were and resuspended in 400ul of 
buffer and transferred FACS tubes 
• Compensation single color controls were 
used to correct fluorescence spillover and 
prevent spectral overlap
Fluorescence-activated single cell sorting 
(FACS) analysis
• The compensations were ran first on the 
BD LSR FACS machine.
• Data were downloaded on our working 
computers and analyzed using FlowJo to 
generate plots and gates to determine 
surface molecule expressions.
Thawing and Growing cells
• Frozen cells were thawed in a 37℃ water 
bath.
• Thawed cells were washed and 
transferred to a T75 flask 
• Cells were grown in R10+BME media at 
37oC/5% CO2
• After cell expansion, 500,000 cells were 
seeded in 6 T-75 flasks 
• Cells were treated with 0, 100, or 300 
u/mL of recombinant mouse IFN-g for 24 
or 72 hours
Harvesting and Staining cells
• After the incubation period, the cells were 
harvested following standard cell splitting 
protocol and transferred to a 96 well plate 
to their assigned well
• The plate was centrifuged for 2 minutes at 
2000 rpm and resuspended in 50 uL of 1x 
Fc block master mix (0.5 Fc block, 49.5 
FACS buffer per well) after decanting the 
supernatant post-centrifugation
• The antibodies (Figure 1) and NIR dye 
were centrifuged for 5 minutes and used 
to make master mixed based on the 
FACS panel designed prior the harvesting
Methods
•Consistent with our hypothesis, IFN-g
upregulated MHC-I and PD-L1
•IFN-g stimulation leads to MHC-II 
expression by some tumor cells, 
specifically less than 20% of all live 
tumor cells
•Further research may be necessary to 
identify whether the relationship is 
significant enough to be taken into 
consideration as a potential target to 
tackle for cancer immunotherapy.
•It appears that the amount of time the 
cells are exposed to IFN-g seems to 
also play a role in the level of MHC-II 
expression, where longer exposure time 
would lead to more MHC-II expression. 
•Perhaps, by upregulating IFN-g, we 
could force solid tumors to express 
more MHC-II than they usually do, 
making them more susceptible to CD4+ 
T-cells.
•When comparing the 100 U/mL and 
300 U/mL groups under the same 
incubation times, there does not seem 
to be any significant difference in MHC-
II expression, possibly due to saturation 
of IFN-g
•Oversaturation of IFN-g stimulation 
over a long period of time may down 
regulate MHC-I and PD-L1 expression.
•Future research could be done to 
check if there is an optimal 
concentration for IFN-g for upregulating 
surface molecule expression.
•While IFN-g is a dominant cytokine for 
upregulating MHC and PD-L1 
expression, other inflammatory signals 
(such as IFN-a) can be explored upon to 
examine whether they also regulate 




List of Fluorescently Conjugated Antibodies
Fluorescent Antibody Expression Implication
PerCP-Cy5.5-CD274 PD-L1 PD-L1(+)
I-A/I-E MHC class II-BV650 MHC-II(+)
Isotype control BV650 MHC-II(-)
H-2Db MHC class 1-APC MHC-I(+)
H-2Kb MHC class 1-PE MHC-I(+)
CD80 (B7.1)-PE/Cy7 CD80(+)
Isotype Control. Hamster IgG-PE/Cy7 CD80(-)





















































































Figure 3. MHC-I and PD-L1 expression charts based 
on mean fluorescent intensity (MFI). 
0 U/mL rIFNg 100 U/mL rIFNg 300 U/mL rIFNg
